Officials of Syntex, Palo Alto, Calif., have notified TheraTech Inc., 417 Wakara Way, it will discontinue development of the ketorolac transdermal patch because of the risk-benefit assessment and its potential for commercial viability.
Dinesh C. Patel, TheraTech president, said, "Although this action by Syntex is disappointing to us, the multiproduct development contract remains in effect and we are also exploring with Syntex product development opportunities utilizing our other delivery technologies."A Syntex official said the decision doesn't effect his company's relationship with TheraTech. Syntex had previously paid TheraTech for achievement of target blood-level profiles and skin-tolerance criteria in clinical studies with the ketorolac patch.
Syntex's decision affects only the ketorolac patch project. It will maintain its equity position in TheraTech, and the Aug. 21, 1991, agreement between the two companies concerning rights to other products to be developed in core therapeutic areas is still in effect.
TheraTech is developing innovative products based on controlled release drug delivery technologies.